Miromatrix Medical Past Earnings Performance
Past criteria checks 0/6
Miromatrix Medical's earnings have been declining at an average annual rate of -43.6%, while the Life Sciences industry saw earnings growing at 20.7% annually. Revenues have been growing at an average rate of 119.2% per year.
Key information
-43.6%
Earnings growth rate
36.6%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 119.2% |
| Return on equity | -176.4% |
| Net Margin | -2,861.1% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely
Oct 28
We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate
Jul 01Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation
Mar 08Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation
Sep 30Miromatrix gets US patent for recellularizing technology for use in organ transplant
Aug 25Miromatrix Medical GAAP EPS of -$0.40 misses by $0.07, revenue of $3.95M
Aug 15Revenue & Expenses Breakdown
How Miromatrix Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -27 | 11 | 18 |
| 30 Jun 23 | 1 | -29 | 11 | 19 |
| 31 Mar 23 | 1 | -30 | 11 | 20 |
| 31 Dec 22 | 1 | -30 | 11 | 20 |
| 30 Sep 22 | 0 | -28 | 10 | 18 |
| 30 Jun 22 | 0 | -26 | 9 | 17 |
| 31 Mar 22 | 0 | -21 | 7 | 14 |
| 31 Dec 21 | 0 | -15 | 5 | 11 |
| 30 Sep 21 | 0 | -10 | 4 | 10 |
| 30 Jun 21 | 0 | -8 | 3 | 8 |
| 31 Mar 21 | 0 | -8 | 2 | 8 |
| 31 Dec 20 | 0 | -10 | 2 | 8 |
| 31 Dec 19 | 0 | -5 | 2 | 7 |
Quality Earnings: MIRO is currently unprofitable.
Growing Profit Margin: MIRO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MIRO is unprofitable, and losses have increased over the past 5 years at a rate of 43.6% per year.
Accelerating Growth: Unable to compare MIRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MIRO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-11.4%).
Return on Equity
High ROE: MIRO has a negative Return on Equity (-176.36%), as it is currently unprofitable.